TXMD

TherapeuticsMD, Inc. NASDAQ Listed May 9, 2007

Healthcare ·Drug Manufacturers - Specialty & Generic ·US · therapeuticsmd.com

$2.01

Mkt Cap $23.3M

52w Low $0.98 52.3% of range 52w High $2.95

50d MA $2.15 200d MA $1.69

P/E (TTM) -42.1x

EV/EBITDA -5.5x

P/B 0.9x

Debt/Equity 0.2x

ROE -2.1%

P/FCF 7.7x

RSI (14) —

ATR (14) —

Beta 0.56

50d MA $2.15

200d MA $1.69

Avg Volume 27.8K

TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and TX-008HR, which are transdermal patch product candidates; and TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

SIC Code

2834

CIK (SEC)

25743

Phone

561 961 1900

951 Yamato Road · Boca Raton, FL 33431 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 30, 2026	AMC	-6.12	-0.05	+99.1%	1.99	-4.5%	+1.5%	-1.0%	+0.0%	+10.0%	-8.2%	—
Nov 12, 2025	AMC	—	0.01	—	1.68	+1.2%	-3.6%	+21.0%	-22.4%	+1.3%	+7.1%	—
Aug 12, 2025	AMC	—	0.05	—	1.11	-0.9%	+4.5%	-0.9%	+1.7%	-2.6%	+1.8%	—
May 13, 2025	AMC	—	-0.06	—	1.52	-0.7%	-3.9%	+0.0%	+2.7%	-1.3%	+0.7%	—
Mar 27, 2025	AMC	0.04	0.02	-45.2%	1.05	-2.9%	-6.5%	-5.8%	+5.9%	+2.0%	-3.0%	—
Nov 12, 2024	AMC	0.04	-0.05	-225.0%	1.50	-0.7%	+0.0%	-2.7%	-4.1%	-7.9%	+0.8%	—
Aug 12, 2024	AMC	0.03	-0.09	-400.0%	1.67	+4.8%	+2.4%	-4.7%	-1.2%	+3.1%	-0.6%	—
May 10, 2024	AMC	0.03	-0.07	-333.3%	2.03	-0.5%	+2.5%	-1.9%	+2.5%	+1.4%	+4.7%	—
Mar 29, 2024	AMC	-0.13	-0.08	+38.5%	—	—	—	—	—	—	—	—
Nov 14, 2023	AMC	-0.15	-0.13	+13.3%	2.01	+0.0%	+17.4%	-0.4%	-3.4%	+28.6%	-4.6%	—
Aug 14, 2023	AMC	-0.07	-0.24	-242.9%	3.85	-0.3%	-0.3%	-4.7%	-0.3%	+2.7%	+1.9%	—
May 15, 2023	AMC	0.06	-0.24	-500.0%	4.39	+5.7%	+0.2%	-4.8%	+1.2%	+1.9%	-0.2%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Aug 17	Cantor Fitzgerald	Maintains	Neutral → Neutral	—	$3.66	$3.50	-4.4%	-0.3%	+2.7%	+1.9%	+0.5%	+2.3%
Jun 7	HC Wainwright & Co.	Downgrade	Buy → Neutral	—	$9.97	$9.89	-0.8%	-0.4%	-0.1%	-0.1%	+0.4%	+0.2%
May 6	Cantor Fitzgerald	Downgrade	Overweight → Neutral	—	$8.50	$9.00	+5.9%	-11.8%	-35.5%	-5.0%	-24.8%	-13.9%
Mar 11	HC Wainwright & Co.	Maintains	Buy → Buy	—	$14.50	$14.50	+0.0%	+0.0%	-6.9%	+22.2%	+12.1%	+5.4%
Nov 12	HC Wainwright & Co.	Maintains	Buy → Buy	—	$33.00	$32.50	-1.5%	-4.5%	-3.2%	-3.3%	-3.4%	+1.8%
Aug 7	Jefferies	Downgrade	Hold → Underperform	—	$80.50	$84.00	+4.3%	+3.7%	-6.0%	-1.3%	+2.6%	-2.5%
May 19	JP Morgan	Downgrade	Overweight → Neutral	—	$59.50	$58.00	-2.5%	-6.7%	+1.8%	+5.3%	+5.0%	-2.4%
Apr 16	Stifel	Maintains	Buy → Buy	—	$43.50	$45.00	+3.4%	+8.0%	+1.1%	+0.0%	-4.2%	+0.0%
Feb 21	H.C. Wainwright	Maintains	Buy → Buy	—	$107.50	$107.50	+0.0%	-4.2%	-7.8%	-2.6%	-3.8%	-6.7%
Aug 14	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$258.00	$262.50	+1.7%	+6.4%	-0.9%	+2.0%	-2.9%	+1.5%
Jul 11	Oppenheimer	Upgrade	Perform → Outperform	—	$240.00	$261.50	+9.0%	+4.0%	+0.2%	+11.4%	+1.1%	-6.6%
May 9	Oppenheimer	Downgrade	Outperform → Perform	—	$209.00	$198.00	-5.3%	+4.5%	-2.7%	+0.9%	+3.7%	+1.3%
Dec 6	Stifel Nicolaus	Maintains	Buy → Buy	—	$308.50	$365.50	+18.5%	+12.8%	-4.3%	-7.5%	+0.0%	-4.5%
Mar 4	Stifel Nicolaus	Maintains	Buy → Buy	—	$337.50	$352.00	+4.3%	+4.6%	+5.2%	+5.0%	-0.3%	+0.4%

Data updated apr 27, 2026 6:15am · Source: massive.com